Equity Profile

BBIO

BRIDGEBIO PHARMA INC

Health CareBiotechnology$13.2B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases and cancers....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Investors will look for signs of revenue growth to gauge market demand for BridgeBio's products and therapies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BBIO Q2-2026 Earnings Preview

Context

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases and cancers. With a market cap of $14 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs through innovative treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.09%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In Q1-2026, BridgeBio reported an EPS of -$0.84, missing estimates by 19.32%. The stock reacted negatively, declining by 0.94% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for BridgeBio's upcoming earnings are cautious, given the recent history of EPS misses. Investors are particularly focused on any updates regarding clinical trials and revenue growth.

Bull Case

If BridgeBio can demonstrate significant progress in its clinical trials and show signs of revenue growth, it could lead to a positive market reaction and renewed investor confidence.

Bear Case

Conversely, if the company continues to miss EPS estimates and fails to provide compelling updates on its clinical pipeline, it may face further stock declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials and when can we expect results?

Updates on clinical trials are crucial for assessing the potential success of BridgeBio's therapies and could significantly influence investor sentiment.

What are the company's revenue projections for the upcoming quarters?

Clear guidance on revenue growth is essential for understanding the company's financial trajectory and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BridgeBio's clinical trials to yield positive results, which could significantly enhance its market position.

Supporting Evidence

The options market is pricing a 20.9% move, suggesting expectations for volatility that may not align with the actual performance.

Insider selling activity could indicate a lack of confidence in the near-term outlook, which the market may not fully appreciate.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and lead to a reevaluation of the stock's potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on whether BridgeBio can turn around its recent performance and provide a clearer outlook for future growth.

Bull Confirmed If

Demonstrating a clear path to profitability with a reduction in EPS losses and positive revenue growth.

Bear Confirmed If

Continued EPS misses and lack of progress in clinical trials, leading to diminished investor confidence.

Pre-Earnings Positioning

Options Market

Implied Move

±20.9%

Historical Avg

±2.2%

Pricing cheap

The options market is pricing in a significant move, indicating that investors are anticipating volatility around the earnings report.

Options are pricing ±1.8% while BBIO has averaged ±2.2% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

41.9%

Calls (144K)P/C Ratio: 0.38Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.7%, with a raw directional average of -2.0% (modestly negative historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$6.0M

80,000 sh

1 insider

Net

$6.0M

Net selling

Most Active Insiders· 8 open-market trades

Chief Executive OfficerKumar Neil
$6.0M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BridgeBio beats expectations, history suggests the stock could see an average increase of around 1.48% the following day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors await further clarity.

Miss

Should the company miss expectations again, history suggests a potential decline of approximately 1.48%, reflecting ongoing concerns about its financial health.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·0 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines and results of ongoing clinical trials.
2Any guidance on revenue expectations for the next quarter.
3Details on cost management strategies and their impact on EPS.
4Insights into market demand for BridgeBio's therapies.
5Management's outlook on competitive positioning within the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases and cancers....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Investors will look for signs of revenue growth to gauge market demand for BridgeBio's products and therapies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BBIO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.09%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In Q1-2026, BridgeBio reported an EPS of -$0.84, missing estimates by 19.32%. The stock reacted negatively, declining by 0.94% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If BridgeBio can demonstrate significant progress in its clinical trials and show signs of revenue growth, it could lead to a positive market reaction and renewed investor confidence.

Bear Case

Conversely, if the company continues to miss EPS estimates and fails to provide compelling updates on its clinical pipeline, it may face further stock declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials and when can we expect results?

Updates on clinical trials are crucial for assessing the potential success of BridgeBio's therapies and could significantly influence investor sentiment.

What are the company's revenue projections for the upcoming quarters?

Clear guidance on revenue growth is essential for understanding the company's financial trajectory and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BridgeBio's clinical trials to yield positive results, which could significantly enhance its market position.

Supporting Evidence

The options market is pricing a 20.9% move, suggesting expectations for volatility that may not align with the actual performance.

Insider selling activity could indicate a lack of confidence in the near-term outlook, which the market may not fully appreciate.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and lead to a reevaluation of the stock's potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on whether BridgeBio can turn around its recent performance and provide a clearer outlook for future growth.

Bull Confirmed If

Demonstrating a clear path to profitability with a reduction in EPS losses and positive revenue growth.

Bear Confirmed If

Continued EPS misses and lack of progress in clinical trials, leading to diminished investor confidence.

Pre-Earnings Positioning

Options Market

Implied Move

±20.9%

Historical Avg

±2.2%

Pricing cheap

The options market is pricing in a significant move, indicating that investors are anticipating volatility around the earnings report.

Options are pricing ±1.8% while BBIO has averaged ±2.2% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

41.9%

Calls (144K)P/C Ratio: 0.38Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$6.0M

80,000 sh

1 insider

Net

$6.0M

Net selling

Most Active Insiders· 8 open-market trades

Chief Executive OfficerKumar Neil
$6.0M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BridgeBio beats expectations, history suggests the stock could see an average increase of around 1.48% the following day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors await further clarity.

Miss

Should the company miss expectations again, history suggests a potential decline of approximately 1.48%, reflecting ongoing concerns about its financial health.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·0 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines and results of ongoing clinical trials.
2Any guidance on revenue expectations for the next quarter.
3Details on cost management strategies and their impact on EPS.
4Insights into market demand for BridgeBio's therapies.
5Management's outlook on competitive positioning within the biotechnology sector.